Adult ALLV-TARGETNCT06727942
Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes
A study testing V-TARGET intervention in people with Adult ALL, run by The University of Texas at Arlington at 1 site in United States.
Trial summary
Age-associated motor and cognitive deficits increase the risk of falls, a major cause of morbidity and mortality. Emerging evidence suggests that inflammatory mediators lead to impaired functional capacity and frailty in the elderly and suggests that immune system mediated inflammation in the brain play an important… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Adult ALL
- What is being tested?
- V-TARGET intervention
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 10 May 2022to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- adults aged up to 75 years old
- able to walk independently, without use of an assistive device
- English speaking
Who cannot join
- self-disclosed limited mobility in joint(s) due to arthritis or other condition that would prevent participation
- any ongoing orthopedic injury
- cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.
- motor/cognitive disorders (Alzheimer's disease, Parkinson's disease, dementia, etc.)
- use of a wheelchair
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Texas at Arlington Movement & Physical Activity Epidemiology Laboratory
Arlington, Texas, 76019
Kinesiology Administrator, 817-272-3109, cindyks@uta.edu
MPAE Lab manager, 817-272-3318, caifang.wu@uta.edu
About this study
Official title: Toward Healthy Living: Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes
Age-associated motor and cognitive deficits increase the risk of falls, a major cause of morbidity and mortality. Emerging evidence suggests that inflammatory mediators lead to impaired functional capacity and frailty in the elderly and suggests that immune system mediated inflammation in the brain play an important role in cognitive decline. Substantial literature has also demonstrated that age-targeted physical activity training are promising strategies for promoting the motor-cognitive process across the adult lifespan. Recently, the virtual reality (VR) application has been implemented in the neuropsychological rehabilitation settings suggesting that the VR-infused daily living activities may benefit the transfer of intervention outcomes and to promote autonomy in function of daily living such as cooking or grocery shopping. However, it remains unclear the effect of the VR-based exercise intervention (motor-cognitive impact) on older adults' cognitive function and fall prevention. The literature suggests that the similarity of VR exercises with real life activities may improve generalizability by extending the transfer of gains of training to everyday living and promote some aspects of quality of life in older adults. It is also unclear to what extent these aging-associated motor- cognitive changes may be affected by VR rehab games and whether systemic- and neuro-inflammation is ameliorated by this novel intervention in older adults.
This purpose of this study is to design and implement a Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes (V-TARGET) intervention, focusing on adults (aged up to 75 years old). The study will compare the effects of V-TARGET intervention (self-paced treadmill-simulator exercise with VR rehab games) against a control group on motor-cognitive function, health-related quality of life (HRQOL), circulating inflammatory markers and cerebral/peripheral blood flow through this 5-week intervention (2 times/week, 30-minutes/session, 10 sessions total).
Read the detailed description
A randomized controlled trial using a repeated measure design with a 1-month follow-up assessment will be employed. The study will compare the effects of V-TARGET intervention (self-paced treadmill exercise augmented by VR rehab games) against an active-control paradigm (self-paced treadmill exercise without VR rehab games) on motor-cognitive function, health-related quality of life (HRQOL), and circulating inflammatory markers through a 5-week V-TARGET intervention (2 times/week, 30-minutes/session, total 10 sessions). Specifically,
Primary Aim 1: To examine the effects of a 5-week V-TARGET intervention on motor function (i.e., balance/mobility and rate of fall), cognitive function (i.e., working memory and executive function), and HRQOL among older adults.
It is hypothesized that after controlling for socio-demographic variables (i.e., age, gender, SES, body mass index [BMI]), and physical activity history, individuals in the V-TARGET group would exhibit more improvement in the motor and cognitive function and better HRQOL after the intervention compared to individuals in the active control group. It is hypothesized that gains made by the experimental group at post-treatment would be maintained or enhanced at the 1-month follow-up.
Secondary Aim 2: To determine whether a 5-week V-TARGET intervention alters circulating inflammatory markers in older adults. Circulating levels of interferon (IFN)-γ, CXCL10, T cell IFN-γ production and cell surface expression of CXCR3 (the receptor for CXCL10) will be measured .
It is hypothesized that V-TARGET intervention will result in downregulation of the T cell/IFN-γ/CXCL10 inflammatory cascade and that these changes represent a potential biological mechanism by which the V-TARGET intervention improves motor-cognitive function in older adults with high risk of fall. It is hypothesized that gains made by the experimental group at post-treatment would be maintained or enhanced at the 1-month follow-up.
Secondary Aim 3: To examine the effects of a 5-week V-TARGET intervention on Cerebrovascular Health among older adults.
It is hypothesized that after controlling for socio-demographic variables (i.e., age, gender, SES, body mass index [BMI]), and physical activity history, individuals in the V-TARGET group would exhibit more improvement in the Cerebrovascular Health after the intervention compared to individuals in the active control group. It is hypothesized that gains made by the experimental group at post-treatment would be maintained or enhanced at the 1-month follow-up.
- Conditions
- Adult ALL
- Being tested
- V-TARGET intervention
- Keywords
- Virtual-Reality, Fall Risk Invention, Physical Activity, Neuromotor Rehabilitation
- Medical subject headings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
V-TARGET interventionDevice
V-TARGET intervention will be delivered through a 360 degree self-paced treadmill in a university clinical laboratory for 5-weeks (2 days/week, 30 minutes/session) with total 10 sessions. The treadmill is the first-of-kind motion platform that an individual can walk and run at self-paced speed in 360 degree (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people. During the V-TARGET intervention, participants will self-pace their locomotor action (walking/running) while they wear the HTC vivo headset and experience daily exercises/games augmented by the VR Therapy System. Therapy System is a library of VR exercises/games targeted on neurological rehabilitation, balance improvement training as well as cognitive therapy suited for variety of conditions, and includes various daily living simulation activities such as Retail Shopping, Gait Training, Cafeteria Experience, and Nature Walk.
| Study group | Role | What they receive |
|---|---|---|
| V-TARGET intervention group | Experimental | All participants in the V-TARGET intervention group will exercise on the Virtuix Omni 360-degree self-paced, non-powered treadmill-simulator in the lab for 5-weeks (2 days/week, 30 minutes/session, 10 sessions total. The treadmill-simulator is a first-of-its-kind motion platform on which an individual can walk and run at a self-paced speed in 360 degrees (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people.
The V-TARGET intervention group will self-pace their locomotor action (walking/running) on the Omni treadmill-simulator while they wear the Pico Neo 2 head-mounted display (HMD) headset and use the Neuro Rehab VR XR Therapy system to experience daily activity exercises/games, including Retail Therapy, Explore (gait training), Lunchtime Adventure, and Nature Walk. Receives: Device: V-TARGET intervention |
| The waitlist control group | No intervention | The control group will not do any VR exercise but will only complete the pre-post and 1-month follow-up assessment upon signing up the study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor Function
The Tinetti scale measures motor function; the total score ranges from 0- 28: a total score of less than or equal to 18 indicates high risk of falling; score range 19-23 indicates moderate risk of falling; and more than or equal to 24 indicates low risk of falling.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Motor skill
The Bruininks Motor Ability Test (BMAT) is a standardized test of gross and fine motor skills for adults and older. It assesses fine motor integration, manual dexterity, coordination, balance and mobility, and strength and flexibility. Each subtest score is converted into scaled scores based on normative data.
The total BMAT score is derived by summing the scores from each domain, which can then be compared to age-based norms. Higher scores indicate better motor abilities, while lower scores may suggest areas that could benefit from intervention or support.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cognitive function: Multitasking test (MTT)
Cognitive function is assessed with CANTAB (Cambridge Neuropsychological Test Automated Battery) using a handheld tablet (10 x 10-inch iPad).
Multitasking test (MTT) is a test of the participant's ability to manage conflicting information provided by the direction of an arrow and its location on the screen and to ignore task-irrelevant information. Outcome measures include response latencies and error scores.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cognitive function: The spatial working memory (SWM) test
Cognitive function is assessed with CANTAB (Cambridge Neuropsychological Test Automated Battery) using a handheld tablet (10 x 10-inch iPad). The spatial working memory (SWM) test requires retention and manipulation of visuospatial information, and provides a measure of strategy as well as working memory errors. Outcome measures include errors and strategies.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Secondary outcomes (10)
Circulating inflammatory markers: percentage of T cells expressing CXCR3
Following a blood draw (~5ml or 1 teaspoon), T cell CXCR3 (the receptor for CXCL10) expression will be assessed by the standard Flow cytometry and calculated in %.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Circulating inflammatory markers: interferon-gamma (IFN-γ)
Following a blood draw (~5ml or 1 teaspoon), interferon-gamma (IFN-γ) is assessed by enzyme-linked immunoassay (ELISA) and calculated in pg/ml.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Circulating inflammatory markers: Circulating CXCL10
Following a blood draw (~5ml or 1 teaspoon), Circulating CXCL10 is assessed by enzyme-linked immunoassay (ELISA) and calculated in pg/ml
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Heart Rate
Heart Rate (beats per minute): Standard heart rate measurement using electrocardiogram
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Systolic arterial blood pressure in the brachial artery (mmHg)
Systolic arterial blood pressure in the brachial artery (mmHg): Standard blood pressure measures
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Diastolic arterial blood pressure in the brachial artery (mmHg)
Diastolic arterial blood pressure in the brachial artery (mmHg): Standard blood pressure measures
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: mean arterial blood pressure in the brachial artery (mmHg)
mean arterial blood pressure in the brachial artery (mmHg): Standard blood pressure measures
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Endothelial Function (% change of brachial artery diameter)
Endothelial Function (% change of brachial artery diameter): Flow Mediated dilation of the brachial artery
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Cerebral blood velocity (centimeters / second)
Cerebral blood velocity (centimeters / second): Measures of blood velocity on the middle cerebral artery using trans-cranial Doppler ultrasound
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Health-related quality of life (HRQOL)
The SF-36 Health Survey is used to measure generic health status and HRQOL. The SF-36 comprises eight health scales: physical functioning (PF; ten items), role limitations due to physical problems (RP; four items), bodily pain (BP; two items), general health (GH; five items), vitality (VT; four items), social functioning (SF; two items), role limitations due to emotional problems (RE; three items), and mental health (MH; five items). The scores range from 0 to 100, with higher scores indicating better functional health and well-being.
Measured: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2024
- Study start10 May 2022
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult ALLStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized into two groups: the intervention group and the control group. All participants will exercise on the Virtuix Omni 360-degree self-paced, non-powered treadmill-simulator in the lab for 5-weeks (2 days/week, 30 minutes/session, 10 sessions total. The treadmill-simulator is a first-of-its-kind motion platform on which an individual can walk and run at a self-paced speed in 360 degrees without risk of falling or colliding with other people. The V-TARGET intervention group will self-pace their locomotor action (walking/running) on the Omni treadmill-simulator while they wear the Pico Neo 2 head-mounted display (HMD) headset and use the Neuro Rehab VR XR Therapy system to experience daily activity exercises/games, including Retail Therapy, Explore (gait training), Lunchtime Adventure, and Nature Walk. The control group will not do any VR exercise but will only complete the pre-post and 1-month follow-up assessment upon signing up the study.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The University of Texas at Arlington
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiangli Gu, PhD, The University of Texas at Arlington
- Investigators
- Xiangli Gu, Principal investigator, University of Texas at Arlington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06727942
- Sponsor's protocol ID
- 2021-0678
- Other IDs
- 2021-0678
- Acronym
- V-TARGET
- Status last verified
- May 2026
- First submitted
- 18 Oct 2024
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: Individual participant data (IPD) may not be shared due to concerns related to participant privacy and confidentiality. While efforts are made to de-identify all data, the sensitive nature of the information collected in this study could potentially lead to the identification of participants if shared publicly. Additionally, current consent forms do not explicitly allow for the sharing of individual data outside of the research team. If future updates to consent or data protection protocols allow for IPD sharing, and with appropriate safeguards in place, it may be reconsidered to share IPD under controlled access conditions. For now, only aggregated data and study results will be shared to maintain the privacy of our participants.
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Toward Healthy Living: Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes
- ClinicalTrials.gov ID
- NCT06727942
- Acronym / sponsor ID
- V-TARGET / 2021-0678
- Conditions
- Adult ALL
- Keywords
- Virtual-Reality, Fall Risk Invention, Physical Activity, Neuromotor Rehabilitation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- The University of Texas at ArlingtonUniversity, hospital or other
- Study start
- 10 May 2022 (actual)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 11 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Age-associated motor and cognitive deficits increase the risk of falls, a major cause of morbidity and mortality. Emerging evidence suggests that inflammatory mediators lead to impaired functional capacity and frailty in the elderly and suggests that immune system mediated inflammation in the brain play an important role in cognitive decline. Substantial literature has also demonstrated that age-targeted physical activity training are promising strategies for promoting the motor-cognitive process across the adult lifespan. Recently, the virtual reality (VR) application has been implemented in the neuropsychological rehabilitation settings suggesting that the VR-infused daily living activities may benefit the transfer of intervention outcomes and to promote autonomy in function of daily living such as cooking or grocery shopping. However, it remains unclear the effect of the VR-based exercise intervention (motor-cognitive impact) on older adults' cognitive function and fall prevention. The literature suggests that the similarity of VR exercises with real life activities may improve generalizability by extending the transfer of gains of training to everyday living and promote some aspects of quality of life in older adults. It is also unclear to what extent these aging-associated motor- cognitive changes may be affected by VR rehab games and whether systemic- and neuro-inflammation is ameliorated by this novel intervention in older adults.
This purpose of this study is to design and implement a Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes (V-TARGET) intervention, focusing on adults (aged up to 75 years old). The study will compare the effects of V-TARGET intervention (self-paced treadmill-simulator exercise with VR rehab games) against a control group on motor-cognitive function, health-related quality of life (HRQOL), circulating inflammatory markers and cerebral/peripheral blood flow through this 5-week intervention (2 times/week, 30-minutes/session, 10 sessions total).
Detailed description
A randomized controlled trial using a repeated measure design with a 1-month follow-up assessment will be employed. The study will compare the effects of V-TARGET intervention (self-paced treadmill exercise augmented by VR rehab games) against an active-control paradigm (self-paced treadmill exercise without VR rehab games) on motor-cognitive function, health-related quality of life (HRQOL), and circulating inflammatory markers through a 5-week V-TARGET intervention (2 times/week, 30-minutes/session, total 10 sessions). Specifically,
Primary Aim 1: To examine the effects of a 5-week V-TARGET intervention on motor function (i.e., balance/mobility and rate of fall), cognitive function (i.e., working memory and executive function), and HRQOL among older adults.
It is hypothesized that after controlling for socio-demographic variables (i.e., age, gender, SES, body mass index [BMI]), and physical activity history, individuals in the V-TARGET group would exhibit more improvement in the motor and cognitive function and better HRQOL after the intervention compared to individuals in the active control group. It is hypothesized that gains made by the experimental group at post-treatment would be maintained or enhanced at the 1-month follow-up.
Secondary Aim 2: To determine whether a 5-week V-TARGET intervention alters circulating inflammatory markers in older adults. Circulating levels of interferon (IFN)-γ, CXCL10, T cell IFN-γ production and cell surface expression of CXCR3 (the receptor for CXCL10) will be measured .
It is hypothesized that V-TARGET intervention will result in downregulation of the T cell/IFN-γ/CXCL10 inflammatory cascade and that these changes represent a potential biological mechanism by which the V-TARGET intervention improves motor-cognitive function in older adults with high risk of fall. It is hypothesized that gains made by the experimental group at post-treatment would be maintained or enhanced at the 1-month follow-up.
Secondary Aim 3: To examine the effects of a 5-week V-TARGET intervention on Cerebrovascular Health among older adults.
It is hypothesized that after controlling for socio-demographic variables (i.e., age, gender, SES, body mass index [BMI]), and physical activity history, individuals in the V-TARGET group would exhibit more improvement in the Cerebrovascular Health after the intervention compared to individuals in the active control group. It is hypothesized that gains made by the experimental group at post-treatment would be maintained or enhanced at the 1-month follow-up.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Participants will be randomized into two groups: the intervention group and the control group. All participants will exercise on the Virtuix Omni 360-degree self-paced, non-powered treadmill-simulator in the lab for 5-weeks (2 days/week, 30 minutes/session, 10 sessions total. The treadmill-simulator is a first-of-its-kind motion platform on which an individual can walk and run at a self-paced speed in 360 degrees without risk of falling or colliding with other people. The V-TARGET intervention group will self-pace their locomotor action (walking/running) on the Omni treadmill-simulator while they wear the Pico Neo 2 head-mounted display (HMD) headset and use the Neuro Rehab VR XR Therapy system to experience daily activity exercises/games, including Retail Therapy, Explore (gait training), Lunchtime Adventure, and Nature Walk. The control group will not do any VR exercise but will only complete the pre-post and 1-month follow-up assessment upon signing up the study.
| Arm | Type | Receives |
|---|---|---|
| V-TARGET intervention group | Experimental | Device: V-TARGET interventionAll participants in the V-TARGET intervention group will exercise on the Virtuix Omni 360-degree self-paced, non-powered treadmill-simulator in the lab for 5-weeks (2 days/week, 30 minutes/session, 10 sessions total. The treadmill-simulator is a first-of-its-kind motion platform on which an individual can walk and run at a self-paced speed in 360 degrees (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people. The V-TARGET intervention group will self-pace their locomotor action (walking/running) on the Omni treadmill-simulator while they wear the Pico Neo 2 head-mounted display (HMD) headset and use the Neuro Rehab VR XR Therapy system to experience daily activity exercises/games, including Retail Therapy, Explore (gait training), Lunchtime Adventure, and Nature Walk. |
| The waitlist control group | No intervention | –The control group will not do any VR exercise but will only complete the pre-post and 1-month follow-up assessment upon signing up the study. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- adults aged up to 75 years old
- able to walk independently, without use of an assistive device
- English speaking
Key exclusion criteria (5 listed)
- self-disclosed limited mobility in joint(s) due to arthritis or other condition that would prevent participation
- any ongoing orthopedic injury
- cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.
- motor/cognitive disorders (Alzheimer's disease, Parkinson's disease, dementia, etc.)
- use of a wheelchair
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| V-TARGET interventionV-TARGET intervention will be delivered through a 360 degree self-paced treadmill in a university clinical laboratory for 5-weeks (2 days/week, 30 minutes/session) with total 10 sessions. The treadmill is the first-of-kind motion platform that an individual can walk and run at self-paced speed in 360 degree (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people. During the V-TARGET intervention, participants will self-pace their locomotor action (walking/running) while they wear the HTC vivo headset and experience daily exercises/games augmented by the VR Therapy System. Therapy System is a library of VR exercises/games targeted on neurological rehabilitation, balance improvement training as well as cognitive therapy suited for variety of conditions, and includes various daily living simulation activities such as Retail Shopping, Gait Training, Cafeteria Experience, and Nature Walk. | Device | V-TARGET intervention group |
Primary outcome
Motor Function
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
The Tinetti scale measures motor function; the total score ranges from 0- 28: a total score of less than or equal to 18 indicates high risk of falling; score range 19-23 indicates moderate risk of falling; and more than or equal to 24 indicates low risk of falling.
Motor skill
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
The Bruininks Motor Ability Test (BMAT) is a standardized test of gross and fine motor skills for adults and older. It assesses fine motor integration, manual dexterity, coordination, balance and mobility, and strength and flexibility. Each subtest score is converted into scaled scores based on normative data. The total BMAT score is derived by summing the scores from each domain, which can then be compared to age-based norms. Higher scores indicate better motor abilities, while lower scores may suggest areas that could benefit from intervention or support.
Cognitive function: Multitasking test (MTT)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cognitive function is assessed with CANTAB (Cambridge Neuropsychological Test Automated Battery) using a handheld tablet (10 x 10-inch iPad). Multitasking test (MTT) is a test of the participant's ability to manage conflicting information provided by the direction of an arrow and its location on the screen and to ignore task-irrelevant information. Outcome measures include response latencies and error scores.
Cognitive function: The spatial working memory (SWM) test
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cognitive function is assessed with CANTAB (Cambridge Neuropsychological Test Automated Battery) using a handheld tablet (10 x 10-inch iPad). The spatial working memory (SWM) test requires retention and manipulation of visuospatial information, and provides a measure of strategy as well as working memory errors. Outcome measures include errors and strategies.
10 secondary outcomes
Circulating inflammatory markers: percentage of T cells expressing CXCR3
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Circulating inflammatory markers: interferon-gamma (IFN-γ)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Circulating inflammatory markers: Circulating CXCL10
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Heart Rate
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Systolic arterial blood pressure in the brachial artery (mmHg)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Diastolic arterial blood pressure in the brachial artery (mmHg)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: mean arterial blood pressure in the brachial artery (mmHg)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Endothelial Function (% change of brachial artery diameter)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Cerebrovascular Health: Cerebral blood velocity (centimeters / second)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Health-related quality of life (HRQOL)
Time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Virtual Reality Rehab-Therapy on Neuromotor Function and Cardiovascular HealthLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data (IPD) may not be shared due to concerns related to participant privacy and confidentiality. While efforts are made to de-identify all data, the sensitive nature of the information collected in this study could potentially lead to the identification of participants if shared publicly. Additionally, current consent forms do not explicitly allow for the sharing of individual data outside of the research team. If future updates to consent or data protection protocols allow for IPD sharing, and with appropriate safeguards in place, it may be reconsidered to share IPD under controlled access conditions. For now, only aggregated data and study results will be shared to maintain the privacy of our participants.
Related trials for Adult ALL
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Not yet recruitingObservational study
Validation of the Healthcare Relationship Assessment Scale (ERA) in Health Sciences Students.
Health Adult Subjects, Communication
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiangli Gu principal investigator
University of Texas at Arlington
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing V-TARGET intervention in people with Adult ALL, run by The University of Texas at Arlington at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Associate Professor (817-272-3318, xiangli.gu@uta.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor Function (time frame: Baseline & immediately following the intervention & and again at 1-month following completion of the intervention.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.